Validation of AML-Score in older adults receiving daunorubicin/cytarabine liposome intensive induction chemotherapy for treatment of secondary acute myeloid leukemia.

被引：0
|
作者：
Schmucker, Abigail
Leiby, Benjamin
Wilde, Lindsay
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19000
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
    Cafaro, Alessandro
    Giannini, Maria B.
    Silimbani, Paolo
    Cangini, Delia
    Masini, Carla
    Di Rora, Andrea Ghelli Luserna
    Simonetti, Giorgia
    Martinelli, Giovanni
    Cerchione, Claudio
    MINERVA MEDICA, 2020, 111 (05) : 455 - 466
  • [42] SECONDARY ACUTE MYELOID LEUKEMIA - FIRST LINE TREATMENT WITH CYTARABINE, DAUNORUBICIN AND CYCLOSPORINE, A PORTUGUESE HOSPITAL'S EXPERIENCE
    Nunes, M.
    Leite, L.
    Chacim, S.
    Ferreira, C.
    Moreira, C.
    Pereira, D.
    Brito, M.
    Marques, M.
    Viterbo, L.
    Martins, A.
    Domingues, N.
    Moreira, I.
    Espirito-Santo, A.
    Oliveira, I.
    Mariz, J.
    HAEMATOLOGICA, 2013, 98 : 521 - 522
  • [43] Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality
    Borthakur, Gautam
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias J.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Pemmaraju, Naveen
    Konopleva, Marina
    Ohanian, Maro
    Wierda, William G.
    Jain, Nitin
    Xiao, Lian-Chun
    Mukherjee, Paromita
    Brandt, Mark
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [44] INFECTION OF ELDERLY PATIENTS RECEIVING HIGH-DOSE CYTARABINE-BASED CHEMOTHERAPY FOR INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA (AML)
    NEMUNAITIS, J
    MEYER, W
    NEMUNAITIS, J
    TAYLOR, E
    RILEY, C
    COOPER, B
    LEUKEMIA RESEARCH, 1994, 18 (08) : 649 - 650
  • [45] Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Faderl, S
    Verstovsek, S
    Cortes, J
    Ravandi, F
    Beran, M
    Garcia-Manero, G
    Ferrajoli, A
    Estrov, Z
    O'Brien, S
    Koller, C
    Giles, FJ
    Wierda, W
    Kwari, M
    Kantarjian, HM
    BLOOD, 2006, 108 (01) : 45 - 51
  • [46] Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
    Versluis, Jurjen
    Flamand, Yael
    Haydu, Erika J.
    Vedula, Rahul S.
    Charles, Anne
    Copson, Kevin
    Wolach, Ofir
    Bendapudi, Pavan
    Belizaire, Roger
    Neuberg, Donna S.
    Luskin, Marlise R.
    Lindsley, R. Coleman
    BLOOD, 2020, 136
  • [47] Evaluation of Early Discharge after Intensive Induction Chemotherapy in Adults with Acute Myeloid Leukemia
    Al-Bahou, Amanda
    Richter, Katherine A.
    Snyder, Matthew
    Rockwell, Sarah J.
    Yun, Seongseok
    Kubal, Timothy E.
    BLOOD, 2021, 138
  • [48] Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study
    Holowiecki, J
    Grosicki, S
    Robak, T
    Kyrcz-Krzemien, S
    Giebel, S
    Hellmann, A
    Skotnicki, A
    Jedrzejczak, WW
    Konopka, L
    Kuliczkowski, K
    Zdziarska, B
    Dmoszynska, A
    Marianska, B
    Pluta, A
    Zawilska, K
    Komarnicki, M
    Kloczko, J
    Sulek, K
    Haus, O
    Stella-Holowiecka, B
    Baran, W
    Jakubas, B
    Paluszewska, M
    Wierzbowska, A
    Kielbinski, M
    Jagoda, K
    LEUKEMIA, 2004, 18 (05) : 989 - 997
  • [49] Daunorubicin, cytarabine and fludarabine (DAF) for the treatment of relapsed/refractory acute myeloid leukemia. Phase II study by the polish adult leukemia group (PALG)
    Holowiecki, J
    Grosicki, S
    Krzemien, S
    Skotnicki, A
    Warzecha, K
    Zdziarska, B
    Stella-Holowiecka, B
    Krawczyk-Kulis, M
    Kopera, M
    Wojciechowska, M
    BLOOD, 2004, 104 (11) : 210B - 210B
  • [50] Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study
    J Holowiecki
    S Grosicki
    T Robak
    S Kyrcz-Krzemien
    S Giebel
    A Hellmann
    A Skotnicki
    W W Jedrzejczak
    L Konopka
    K Kuliczkowski
    B Zdziarska
    A Dmoszynska
    B Marianska
    A Pluta
    K Zawilska
    M Komarnicki
    J Kloczko
    K Sulek
    O Haus
    B Stella-Holowiecka
    W Baran
    B Jakubas
    M Paluszewska
    A Wierzbowska
    M Kielbinski
    K Jagoda
    Leukemia, 2004, 18 : 989 - 997
12345